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Abstract
Introduction: The aim of the study was to investigate at long-term follow-up
the incidence of appropriate implantable cardioverter-defibrillator (ICD) shocks
and of all-cause mortality in patients with ICDs with ischemic cardiomyopathy
versus nonischemic cardiomyopathy.
Material and methods: ICDs were implanted in 485 patients with ischemic
cardiomyopathy and in 299 patients with nonischemic cardiomyopathy, all of
whom had coronary angiography. Baseline characteristics were not significantly
different between the 2 groups. Follow-up was 965 days in patients with
ischemic cardiomyopathy versus 1039 days in patients with nonischemic
cardiomyopathy (p not significant). The ICDs were interrogated every 3 months
to see if shocks occurred. 
Results: Appropriate ICD shocks occurred in 179 of 485 patients (37%) with
ischemic cardiomyopathy and in 93 of 299 patients (31%) with nonischemic
cardiomyopathy (p not significant). All-cause mortality occurred in 162 of 485
patients (33%) with ischemic cardiomyopathy and in 70 of 299 patients (23%)
with nonischemic cardiomyopathy (p = 0.002).
Conclusions: The incidence of appropriate ICD shocks was not significantly
different at 33-month follow-up in patients with ischemic cardiomyopathy versus
nonischemic cardiomyopathy. However, patients with ischemic cardiomyopathy
had a significantly higher incidence of all-cause mortality than patients with
nonischemic cardiomyopathy (p = 0.002).
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Introduction
Implantable cardioverter-defibrillators (ICDs) have been shown to reduce
all-cause mortality in patients with ischemic heart disease [1-5] and in
patients with nonischemic cardiomyopathy [5, 6]. At 30-month follow-up
of 148 patients with ischemic heart disease and an ICD and of 60 patients
with nonischemic heart disease and an ICD, ventricular tachycardia and
ventricular fibrillation episodes per month were not significantly different
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Copyright © 2010 Termedia & Banachbetween the 2 groups [7]. At 19-month follow-up
of 105 patients with ischemic cardiomyopathy and
of 48 patients with nonischemic cardiomyopathy
and nonsustained ventricular tachycardia,
appropriate ICD shocks occurred in 50% of patients
with nonischemic cardiomyopathy versus 36% of
patients with ischemic cardiomyopathy (p not
significant) [8]. 
The incidence of appropriate ICD shocks and of
all-cause mortality at long-term follow-up in a large
number of patients with ischemic cardiomyopathy
versus nonischemic cardiomyopathy needed to be
investigated. The present article reports the
incidence of appropriate ICD shocks and of all-cause
mortality at 33-month follow-up in 485 patients
with ischemic cardiomyopathy and in 299 patients
with nonischemic cardiomyopathy. 
Material and methods
There were 485 patients (83% men and 17%
women), mean age 71 years, with ischemic
cardiomyopathy and an ICD and 299 (78% men and
22% women), mean age 71 years, with nonischemic
cardiomyopathy and an ICD. All 485 patients with
ischemic cardiomyopathy had coronary angio  -
graphic evidence of obstructive coronary artery
disease and a reduced left ventricular ejection
fraction. All 299 patients with nonischemic cardio  -
myopathy had coronary angiographic evidence of
no coronary artery disease and a reduced left
ventricular ejection fraction. 
All 485 patients with ischemic cardiomyopathy
and 299 patients with nonischemic cardiomyopathy
had an ICD implanted for secondary or primary
prevention of sudden cardiac death as a class
I indication according to the American College of
Cardiology/American Heart Association guidelines
for implantation of an ICD in patients with ischemic
or nonischemic cardiomyopathy [9]. All patients
with ischemic cardiomyopathy had complete
revascularization of obstructive coronary artery
disease [10] by percutaneous coronary intervention
or by coronary artery bypass graft surgery.
At follow-up every 3 months, the ICD was
interrogated to see if any shocks occurred. The
shocks were further evaluated by an electro  -
physiologist viewing the intracardiac electrocardio  -
grams to see if they were appropriate. Appropriate
ICD shocks were for the treatment of ventricular
tachycardia or ventricular fibrillation.
Student’s  t-tests were used to compare
continuous variables between the groups. Chi-
square tests and Fisher’s exact tests were used to
compare dichotomous variables between the
groups. 
The institutional review boards of Westchester
Medical Center and of New York Medical College
approved this study.
Results
Table I shows the baseline characteristics of the
patients with ischemic cardiomyopathy and an ICD
and of the patients with nonischemic cardio  -
myopathy and an ICD. No significant differences
were present between the 2 groups.
Table II shows at 33-month follow-up the
incidence of appropriate ICD shocks and of all-cause
mortality in patients with ischemic cardiomyopathy
versus nonischemic cardiomyopathy. Table II also
shows levels of statistical significance. Sixty-three
of 179 ischemic cardiomyopathy patients (35%) who
had appropriate ICD shocks and 31 of 93 nonis  -
chemic cardiomyopathy patients (33%) who had
appropriate ICD shocks died (p not significant).
Inappropriate ICD shocks occurred in 38 of 485
ischemic cardiomyopathy patients (8%) and in 21
of 299 nonischemic cardiomyopathy patients (7%)
(p not significant). 
Of the 162 patients with ischemic cardio  myopathy
who died, 91 (56%) died of congestive heart failure,
48 (30%) died of sudden cardiac death, 11 (7%) died
of fatal myocardial infarction, and 12 (7%) died of
a noncardiac cause. Of the 70 patients with
nonischemic cardio  myopathy who died, 42 (60%)
died of congestive heart failure, 22 (31%) died of
sudden cardiac death, 0 (0%) died of fatal myocardial
Variable Ischemic  Nonischemic 
cardiomyopathy cardiomyopathy
(n = 485) (n = 299)
Age [years] 71 ±11 71 ±13
Men, n (%) 402 (83) 233 (78)
Smoker, n (%) 104 (21) 56 (19)
Hypertension, n (%) 285 (59) 178 (60)
Diabetes mellitus, n (%) 61 (13) 34 (11)
Dyslipidemia, n (%)  354 (73) 200 (67)
Left ventricular  32 ±10 33 ±11
ejection fraction [%]
ACE inhibitors or  245 (51) 149 (50)
angiotensin receptor 
blockers, n (%)
Beta-blockers, n (%) 301 (62) 180 (60)
Statins, n (%)  349 (72) 197 (66)
Digoxin, n (%) 106 (22) 72 (24)
Amiodarone, n (%)  114 (24) 56 (19)
Sotalol, n (%) 23 (5) 8 (3)
Follow-up [days] 965 ±961 1039 ±1037
Table I. Baseline characteristics of  patients with
implantable cardioverter-defibrillators with ischemic
cardiomyopathy vs. nonischemic cardiomyopathy
No significant differences were present between the 2 groups
ACE – angiotensin-converting enzyme
Ischemic versus nonischemic cardiomyopathy 
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The only significant difference in cause of death
between the 2 groups was fatal myocardial infarction
(p = 0.03 by Fisher’s exact test). 
Discussion
ICDs have been shown to reduce all-cause
mortality in patients with ischemic heart disease
[1-5] and in patients with nonischemic cardio  -
myopathy [5, 6]. At 30-month follow-up of 148
patients with ischemic heart disease and an ICD
and of 60 patients with nonischemic heart disease
and an ICD, ventricular tachycardia and ventricular
fibrillation episodes per month were not
significantly different between the 2 groups [7]. At
19-month follow-up of 105 patients with ischemic
cardiomyopathy and of 48 patients with
nonischemic cardiomyopathy and nonsustained
ventricular tachycardia, appropriate ICD shocks
occurred in 50% of patients with nonischemic
cardiomyopathy versus 36% of patients with
ischemic cardiomyopathy (p not significant). At 
33-month follow-up of 485 patients with ische-
mic cardiomyopathy and of 299 patients with
nonischemic cardiomyopathy in the present study,
the incidence of appropriate ICD shocks was 37%
in patients with ischemic cardiomyopathy versus
31% in patients with nonischemic cardiomyopathy
(p not significant). Unlike the other 2 studies [7, 8],
there was no significant difference in baseline
characteristics between patients with ischemic
versus nonischemic cardiomyopathy in the present
study. In other studies, appropriate ICD shocks
occurred at 33-month follow-up in 329 of 1,038
patients (32%) [11], at 70-month follow-up in 421
of 1,382 patients (31%) [12], at 17-month follow-up
in 169 of 719 patients (24%) in the Multicenter
Automatic Defibrillator Implantation Trial II [13], 
at 29-month follow-up in 33 of 229 patients 
(14%) with nonischemic cardiomyopathy in the
Defibrillators in Non-Ischemic Cardiomyopathy
Treatment Evaluation Trial [14], and at 31-month
follow-up in 52 of 140 patients (37%) with
nonischemic cardiomyopathy [15]. Since the
incidence of appropriate ICD shocks in the present
study and in those previously reported [11-15] varied
from 14% to 37%, this should be considered
a limitation of the current guidelines for ICD
implantation. Patients in our study with appropriate
ICD shocks who died died of congestive heart
failure or fatal myocardial infarction instead of
sudden cardiac death.
In the present study, the low use of angiotensin-
converting enzyme inhibitors or angiotensin
receptor blockers (51% in patients with ischemic
cardiomyopathy and 50% in patients with
nonischemic cardiomyopathy) was due to low blood
pressure or renal insufficiency in patients. Statins
were administered to 197 of 299 patients (66%)
with nonischemic cardiomyopathy because these
197 patients had dyslipidemia. 
Confounding factors for appropriate ICD shocks
and for all-cause mortality are listed in Table I.
Statistical analysis showed no significance
difference in any of the confounding variables
between patients with ischemic cardiomyopathy
versus nonischemic cardiomyopathy.
In the study by Ermis et al. [7], there were 250
patients with ICDs. Mortality was 19% in patients
with ischemic cardiomyopathy versus 11% in
patients with nonischemic cardiomyopathy (p value
not stated). The number of patients with
nonischemic cardiomyopathy versus ischemic
cardiomyopathy, the follow-up time for each group,
and the baseline characteristics of each group for
the 250 patients are not stated [7].
In the study by Evonich et al. [8], at 19-month
follow-up, 12 of 105 patients (11%) with ischemic
cardiomyopathy and 2 of 48 patients with
nonischemic cardiomyopathy (4%) had died (p not
significant). In the present study, at 33-month
follow-up, 162 of 485 patients (33%) with ischemic
cardiomyopathy and 70 of 299 patients (23%) with
nonischemic cardiomyopathy had died (p = 0.002). 
In conclusion, the present study and 2 smaller
studies [7, 8] showed no significant difference in
appropriate ICD shocks at follow-up between
patients with ischemic cardiomyopathy and
nonischemic cardiomyopathy. The present study
showed a significantly higher mortality at follow-up
in patients with ischemic cardiomyopathy versus
nonischemic cardiomyopathy and no significant
differences in baseline characteristics (p = 0.002).
The small number of patients with nonischemic
cardiomyopathy in the 2 other studies is a limitation
for mortality data in these studies [7, 8]. Additional
studies with large numbers of patients with ischemic
cardiomyopathy and nonischemic cardiomyopathy
with ICDs are needed to confirm our data.
Variable Ischemic  Nonischemic  p value
cardiomyopathy cardiomyopathy
(n = 485) (n = 299)
Appropriate  179 (37) 93 (31) NS
ICD shocks, 
n (%)
Mortality,  162 (33) 70 (23) 0.002
n (%)
Table II.  Incidence of appropriate cardioverter-
defibrillator shocks and of mortality in patients with
ischemic cardiomyopathy vs. nonischemic cardio  -
myopathy
ICD – implantable cardioverter-defibrillator, NS – not significant
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